The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

"Even if I didn't lose another pound, I'd take this drug as long as I could," Halstead said. "But at $700 a month, that's not going to happen." Even as weight loss drugs such as Wegovy and ...

Novo Nordisk, which funded both recent trials, sells semaglutide for diabetes under the name Ozempic and for weight loss, as Wegovy. Both drugs have been in short supply for most of the last two ...

The weight loss drug Wegovy may do more than help people lose weight New trial results show the weight-loss medication Wegovy can also cut heart attack and stroke risks, according to the drug's maker.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them. Why your co-pay for weight loss drugs like Wegovy just went through the roof.

As the popularity of medications for weight loss, such as Ozempic and Wegovy, surges across North America, new research ...

Novo Nordisk has introduced Wegovy, a once-weekly weight-loss injection, in India. The drug aims to manage obesity and reduce ...

"Weight-loss drugs like Wegovy may be covered, depending on the member's benefit plan," a spokesperson for the company said. Many other insurance carriers also determine coverage based on what ...

Diabetes drugs Wegovy and Ozempic, which have gained popularity as weight-loss drugs, face major supply issues, drugmaker Novo Nordisk admitted, as the company struggles with surging demand.

Weight loss drugs such as Ozempic, Wegovy could spell trouble for the diet industry By . Associated Press. Published April 25, 2024, 5:54 p.m. ET.